NVS Related Hot List
-
Novartis Acquires Genoptix (GXDX) for $25/Share
-
Novartis (NVS) Acquires Remaining Alcon (ACL) Shares for $168/Share
-
Novartis AG (NVS) Exercises Option on Alcon (ACL), Offers To Acquire Remaining Shares for $153
-
Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
-
Novartis (NVS) Pulls Zelnorm After Cardiovascular Risks
-
Avanir Pharmaceuticals (AVNR) Announces Business Collaboration Updates and Restructuring Plan
-
WSJ Reports FDA Issues 'Approvable Letter' to Novartis (NVS) for Diabetes Drug
-
Cell Therapeutics (CTIC) Soars On License Deal with Novartis (NVS) for XYOTAX
-
Momenta Pharmaceuticals (MNTA) Announces Collaboration with Sandoz (NVS)
-
Human Genome (HGSI) licensing agreement with Novartis for Albuferon
-
Genelabs (GNLB) Soars on Deal with Novartis (NVS)
-
Chiron (CHIR) and Novartis AG (NVS) Amend Merger Deal
-
Idenix Pharma (IDIX) Said Novartis Exercised its Option to License Valopicitabine
-
NVS Buys CHIR for $45/Share
-
NVS and ALNY Announce Alliance
-
CHIR Rejects NVS $40/Share Offer
-
NVS Offers To Buy Rest of CHIR for $40/Share
-
MNTA Files ANDA For Generic Lovenox
-
ANDS Higher After Deal With Novartis
-
PDII Warns Big for FY05; 1M Share Buyback
-
AVN in Development and Commercialization Agreement with Novartis
-
Stem Cells Stocks Up After WSJ Reports Big Firms Getting Involved in Embryonic Research
-
DNA is Higher After SHR/NVS Setback
Back to NVS Stock Lookup
